Investments in unlisted growth companies in the life science sector
Normal Pressure Hydrocephalus is a significantly underdiagnosed condition with dementia-like symptoms. Even though up to 80% of the NPH population get better after surgery, only about 20% get the correct treatment. Lack of reliable diagnostics is one reason for this undertreatment.
Likvor offers a patented and CE certified system that helps caregivers to diagnose the condition and follow-up treatment results by measuring the dynamics of the spinal fluid in the brain.
The company has clients in six countries in Europe and had a revenue of 3.7 MSEK in 2017. Consumables account for an increasing share of the revenue. The market is growing and ageing populations around the world drives market demand.
Lipigon Pharmaceuticals - launching shortly
Lipigon develops orphan drugs for people with lipid disorders and other cardiometabolic risk factors. The company’s main program targets the disease HoFH:
Large medical need. Today’s drugs are not sufficiently efficient, and lack of treatment may cause cardiovascular diseases already at the age of 20-30 years.
Short time to clinical trials. Lipisense has been tested in animal models with promising results. Initial test of toxicity and tolerability has been completed without remarks. The company targets clinical phase 1 studies already in 2020.
Large market. The total market for drugs targeting HoFH is estimated to 1,500 million dollars per year.
Medpro's business is to acquire and run general practices and specialist practices in smaller towns in the south of Sweden. They use a design in healthcare concept with a clear customer focus.
Raytelligence has developed a radar sensor and a cloud based platform for monitoring people's breath, heart frequence and positioning. The company focuses on care of elderly in their homes.